Stamford Health
Stamford Health

Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate with Immuno-therapy

Back to Results

Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate with Immuno-therapy

DF/HCC 20-614 – Combinations of Sacituzumab Govitecan plus Enfortumab Vedotin and Pembrolizumab for Metastatic Urothelial Carcinoma: the Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate with Immuno-therapy (DAD-IO) Phase I/II Trial (NCT04724018)

Principal Investigator(s)

Anthony Gulati, MD

Location

Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-358-8879

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.

ACCEPT AND CLOSE